BIOCRYST PHARMACEUTICALS INC - BCRX

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Mar 26, 2026 SCHEDULE 13G/A The Vanguard Group 0.0% 0 View
Feb 12, 2026 SCHEDULE 13G/A Deerfield Mgmt, L.P. 6.81% 14,341,000 View
Feb 12, 2026 SCHEDULE 13G/A Deerfield Management Company, L.P. 6.81% 14,341,000 View
Feb 12, 2026 SCHEDULE 13G/A Deerfield Partners, L.P. 6.81% 14,341,000 View
Feb 12, 2026 SCHEDULE 13G/A James E. Flynn 6.81% 14,341,000 View
Feb 09, 2026 SCHEDULE 13G STATE STREET CORPORATION 5.3% 11,073,211 View
Nov 12, 2025 SCHEDULE 13G RA Capital Management, L.P. 7.3% 15,302,186 View
Nov 12, 2025 SCHEDULE 13G Peter Kolchinsky 7.3% 15,302,186 View
Nov 12, 2025 SCHEDULE 13G Rajeev Shah 7.3% 15,302,186 View
Nov 12, 2025 SCHEDULE 13G RA Capital Healthcare Fund, L.P. 7.3% 15,302,186 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.